Piyasa Haberleri

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

FUJIY Q1 Earnings Fall Y/Y on Bio CDMO Costs, Revenues Rise

FUJIFILM's Q1 revenue hit a record yen 826.5 billion, but earnings fell 30% as Bio CDMO costs and restructuring weighed on profitability.

İlgili Semboller 1

F FUJIY FUJIY

Kaynak: Zacks Investment Research

0 0 0

Kaynak: CNBC Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it

Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to run, the CEO revealed on the conference call.

İlgili Semboller 1

D DOCS DOCS

Kaynak: CNBC

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Construction Partners (ROAD) Q3 Earnings and Revenues Surpass Estimates

Construction Partners (ROAD) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $0.81 per share a year ago.

İlgili Semboller 1

R ROAD ROAD

Kaynak: Zacks Investment Research

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.

İlgili Semboller 1

T TMCI TMCI

Kaynak: Zacks Investment Research

Official Partner ITBFX Start Trading

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.27 per share a year ago.

İlgili Semboller 1

R RPID RPID

Kaynak: Zacks Investment Research

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Starz Entertainment Corp. (STRZ) Reports Q2 Loss, Tops Revenue Estimates

Starz Entertainment Corp. (STRZ) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.23 per share a year ago.

İlgili Semboller 1

S STRZ STRZ

Kaynak: Zacks Investment Research

Official Partner ITBFX Start Trading

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

ARKO Corp. (ARKO) Q2 Earnings Lag Estimates

ARKO Corp. (ARKO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.16 per share a year ago.

İlgili Semboller 1

A ARKO ARKO

Kaynak: Zacks Investment Research

Official Partner ITBFX Start Trading

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.

İlgili Semboller 1

G GYRE GYRE

Kaynak: Zacks Investment Research

0 0 0

Kaynak: Zacks Investment Research Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

Johnson Outdoor (JOUT) Q3 Earnings and Revenues Top Estimates

Johnson Outdoor (JOUT) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.

İlgili Semboller 1

J JOUT JOUT

Kaynak: Zacks Investment Research

0 0 0

Kaynak: Newsfile Corp Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

MONDAY DEADLINE: Berger Montague Advises ADMA Biologics, Inc. (ADMA) Investors to Inquire About a Securities Fraud Class Action by August 10, 2026

Philadelphia, Pennsylvania--(Newsfile Corp. - August 7, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company") on behalf of investors who purchased or acquired ADMA common stock during the period from August 9, 2024 through March 25, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired ADMA securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.

İlgili Semboller 1

A ADMA ADMA

Kaynak: Newsfile Corp

0 0 0

Kaynak: Seeking Alpha Haber Ajansı

1 ay önce

Hisse Senedi Orta Önem

TPG RE Finance Trust: We Continue To Find The Series C Preferred Shares Attractive

TPG Real Estate Finance Trust (TRTX) Series C Preferred (TRTX.PR.C) remains a Buy, supported by robust Q2 2026 financials and prudent portfolio management. TRTX has reduced office exposure to 4.3% and shifted toward multifamily and industrial assets, mitigating sector risk. Leverage increased to 3.3x, balanced by conservative underwriting and a capital structure reset with long-term, non-mark-to-market debt.

İlgili Semboller 1

T TPG TPG

Kaynak: Seeking Alpha

0 0 0